AUTOLUS THERAPEUTICS PLC's ticker is AUTL and the CUSIP is 05280R100. A total of 73 filers reported holding AUTOLUS THERAPEUTICS PLC in Q4 2021. The put-call ratio across all filers is 0.49 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $175 | -91.2% | 92 | -87.9% | 0.00% | – |
| Q3 2022 | $2,000 | -33.3% | 758 | -20.8% | 0.00% | – |
| Q2 2022 | $3,000 | -40.0% | 957 | -22.6% | 0.00% | – |
| Q1 2022 | $5,000 | -44.4% | 1,236 | -29.2% | 0.00% | – |
| Q4 2021 | $9,000 | -57.1% | 1,745 | -45.5% | 0.00% | – |
| Q3 2021 | $21,000 | -4.5% | 3,199 | -2.2% | 0.00% | – |
| Q2 2021 | $22,000 | +450.0% | 3,271 | +402.5% | 0.00% | – |
| Q1 2021 | $4,000 | -55.6% | 651 | -36.0% | 0.00% | – |
| Q4 2020 | $9,000 | -67.9% | 1,017 | -57.5% | 0.00% | – |
| Q3 2020 | $28,000 | -30.0% | 2,393 | -5.2% | 0.00% | – |
| Q2 2020 | $40,000 | +37.9% | 2,525 | -48.6% | 0.00% | – |
| Q1 2020 | $29,000 | +7.4% | 4,909 | +140.5% | 0.00% | – |
| Q4 2019 | $27,000 | +200.0% | 2,041 | +194.9% | 0.00% | – |
| Q3 2019 | $9,000 | +28.6% | 692 | +49.1% | 0.00% | – |
| Q2 2019 | $7,000 | -12.5% | 464 | +75.1% | 0.00% | – |
| Q1 2019 | $8,000 | – | 265 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 21,346,829 | $49,738,112 | 74.10% |
| TFG Asset Management GP Ltd | 12,000,000 | $27,960,000 | 5.10% |
| Paradigm Biocapital Advisors LP | 14,406,782 | $33,567,802 | 2.28% |
| Lynx1 Capital Management LP | 1,363,025 | $3,175,848 | 2.10% |
| Deep Track Capital, LP | 15,000,000 | $34,950,000 | 1.35% |
| Affinity Asset Advisors, LLC | 1,992,466 | $4,642,446 | 1.31% |
| DAFNA Capital Management LLC | 928,253 | $2,162,829 | 0.67% |
| Frazier Life Sciences Management, L.P. | 3,746,857 | $8,730,177 | 0.58% |
| ARMISTICE CAPITAL, LLC | 6,900,000 | $16,077,000 | 0.25% |
| Blackstone Inc. | 20,485,611 | $47,731,474 | 0.20% |